Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

JQ-1

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Roche

Drug class:

BET inhibitor

Related drugs:

‹

›

MAF overexpression	Multiple Myeloma	MAF overexpression	Multiple Myeloma	JQ-1 + 10058-F4 Resistant: C3 – Early Trials JQ-1 + 10058-F4 Resistant : C3	JQ-1 + 10058-F4 Resistant: C3 – Early Trials JQ-1 + 10058-F4 Resistant : C3
EPCAM expression	Triple Negative Breast Cancer	EPCAM expression	Triple Negative Breast Cancer	JQ-1 Resistant: C3 – Early Trials JQ-1 Resistant : C3	JQ-1 Resistant: C3 – Early Trials JQ-1 Resistant : C3
SOX9 expression	Triple Negative Breast Cancer	SOX9 expression	Triple Negative Breast Cancer	JQ-1 Resistant: C3 – Early Trials JQ-1 Resistant : C3	JQ-1 Resistant: C3 – Early Trials JQ-1 Resistant : C3
GJA1 expression	Triple Negative Breast Cancer	GJA1 expression	Triple Negative Breast Cancer	JQ-1 Resistant: C3 – Early Trials JQ-1 Resistant : C3	JQ-1 Resistant: C3 – Early Trials JQ-1 Resistant : C3
CD24 expression	Triple Negative Breast Cancer	CD24 expression	Triple Negative Breast Cancer	JQ-1 Resistant: C3 – Early Trials JQ-1 Resistant : C3	JQ-1 Resistant: C3 – Early Trials JQ-1 Resistant : C3
BRD4 overexpression	Retinoblastoma	BRD4 overexpression	Retinoblastoma	JQ-1 Sensitive: D – Preclinical JQ-1 Sensitive : D	JQ-1 Sensitive: D – Preclinical JQ-1 Sensitive : D
MYCN amplification	Neuroblastoma	MYCN amplification	Neuroblastoma	JQ-1 + panobinostat Sensitive: D – Preclinical JQ-1 + panobinostat Sensitive : D	JQ-1 + panobinostat Sensitive: D – Preclinical JQ-1 + panobinostat Sensitive : D
MLL rearrangement	Leukemia	MLL rearrangement	Leukemia	JQ-1 Sensitive: D – Preclinical JQ-1 Sensitive : D	JQ-1 Sensitive: D – Preclinical JQ-1 Sensitive : D
P2RY8-CRLF2 fusion	B Acute Lymphoblastic Leukemia	P2RY8-CRLF2 fusion	B Acute Lymphoblastic Leukemia	JQ-1 Sensitive: D – Preclinical JQ-1 Sensitive : D	JQ-1 Sensitive: D – Preclinical JQ-1 Sensitive : D
MYC expression	Multiple Myeloma	MYC expression	Multiple Myeloma	JQ-1 Sensitive: D – Preclinical JQ-1 Sensitive : D	JQ-1 Sensitive: D – Preclinical JQ-1 Sensitive : D
STK11 mutation	Non Small Cell Lung Cancer	STK11 mutation	Non Small Cell Lung Cancer	JQ-1 Resistant: D – Preclinical JQ-1 Resistant : D	JQ-1 Resistant: D – Preclinical JQ-1 Resistant : D
KRAS Q61K	Non Small Cell Lung Cancer	KRAS Q61K	Non Small Cell Lung Cancer	JQ-1 Sensitive: D – Preclinical JQ-1 Sensitive : D	JQ-1 Sensitive: D – Preclinical JQ-1 Sensitive : D